A review article noted that preclinical studies established that anti-TIGIT and anti-PD-1 combination therapies enhance the expansion of CD8+ TILs and trigger cytotoxic responses to melanoma more effectively relative to checkpoint blockade alone [43]. This evidence concerns the gene PDCD1 and melanoma.